You are here
Jon's Blog
Post date | ||
---|---|---|
Mutant-morphant mismatch but no genetic compensation |
Zebrafish Chromosome 14 Gene Differential Expression in the fmr1 h u2787 Model of Fragile X Syndrome. https://www.frontiersin.org/articles/10.3389/fgene.2021.625466/full |
Friday, June 18, 2021 - 08:14 |
Morphant vs mutant: "...this knockout line is deemed unsuitable for our study." |
Here’s a nice description of why, in this study, morphants are preferable to mutants. |
Friday, June 11, 2021 - 11:53 |
Review of neurodegenerative disease and splice modulation |
Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies. https://translationalneurodegeneration.biomedcentral.com/articles/10.118... |
Monday, May 24, 2021 - 13:32 |
Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease (Review) |
Therapeutic Modulation of RNA Splicing in Malignant and Non-Malignant Disease. |
Monday, May 17, 2021 - 11:33 |
SARS-CoV-2 RNA targets for steric blocking |
Potantial targets for steric blocking on the SARS-CoV-2 genome and transcripts. The SARS-CoV-2 RNA interactome. https://www.sciencedirect.com/science/article/pii/S1097276521003270 |
Monday, May 17, 2021 - 10:23 |
Positive control, human and mouse splice modification |
Flynn LL, Mitrpant C, Adams A, Pitout IL, Stirnweiss A, Fletcher S, Wilton SD. Targeted SMN Exon Skipping: A Useful Control to Assess In Vitro and In Vivo Splice-Switching Studies. Biomedicines. 2021;9(5):552. doi:10.3390/biomedicines9050552 |
Friday, May 14, 2021 - 11:52 |
MO knockdown of ectopic GFP in axlotl |
There are few papers reporting using a Morpholino to directly target GFP in vivo; here is one example. |
Friday, April 23, 2021 - 11:21 |
Oligo types, therapeutic Morpholinos, upregulation with Morpholinos |
Here are some types of oligos sorted by their mechanisms. RNase-H dependent
RNase-independent (steric blocking oligos)
Argonaute dependent
About the Morpholino drugs |
Thursday, April 15, 2021 - 09:24 |
Review of oligo delivery for therapeutics |
Hammond SH et al. Delivery of oligonucleotide-based therapeutics: challenges and opportunities. Embo Mol Med. 2021:e13243. doi: 10.15252/emmm.202013243 |
Wednesday, April 7, 2021 - 09:48 |
Review of mutant-morphant discrepency & genetic compensation |
Salanga CM, Salanga MC. Genotype to Phenotype: CRISPR Gene Editing Reveals Genetic Compensation as a Mechanism for Phenotypic Disjunction of Morphants and Mutants. Int J Mol Sci. 2021;22(7),3472. doi:10.3390/ijms22073472 |
Monday, March 29, 2021 - 13:39 |